May 2018
Starting from:
£99 + VAT
Format: DOWNLOADABLE PDF
The conference considered the future for regenerative medicine, advanced therapies and stem cell research - examining key issues for the UK’s research infrastructure, regulatory environment and appraisal processes, as well as the challenges for responding to Brexit.
Key areas of discussion on the day included:
- The potential impact of key recommendations from the Life Sciences Sector Deal and the Life Sciences Industrial Strategy;
- Opportunities for aligning the regulatory work of NICE and MHRA through a ‘one-stop shop’;
- Challenges for implementing the Government response to the Accelerated Access Review;
- Further action that might be taken to address ethical concerns;
- Priorities for developing a new relationship with EU regulatory bodies on Advanced Therapy Medicinal Products;
- Challenges around the costs associated with regenerative medicine and advanced therapies, and allowing patient access safely; and
- The viability of extending the Cancer Drugs Fund to other areas which might have patient benefits and prove to be cost effective.
